Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.69 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519767 | 0.94 | HCRTR1 (0.71) | HCRTR1HCRTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15519701 | 0.93 | HCRTR1 (0.61) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL15518985 | 0.88 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL15522028 | 0.83 | HCRTR2 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL16648754 | 0.82 | HCRTR1 (1.00) | HCRTR1HCRTR2PPARGPPARA | |
| SCHEMBL15519116 | 0.79 | HCRTR1 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL15520240 | 0.79 | KDM4E (0.51) | HCRTR1HCRTR2KDM4ENPC1ALDH1A1 | |
| SCHEMBL13833288 | 0.77 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL16648702 | 0.76 | HCRTR1 (1.00) | HCRTR1HCRTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15521943 | 0.75 | HCRTR1 (0.48) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2708537-A1 | HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | HCRTR1 2/4885HCRTR2 1/4885KDM4E 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.